CITIUS ONCOLOGY, INC.
CITIUS ONCOLOGY, INC. (CTOR): 5 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.4 months
D/E 1.86 · 8% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for CITIUS ONCOLOGY, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$63.2M
Cash
$2.6M
Quarterly Burn
$3.8M
Runway
8.4 mo
Revenue
$1.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| E7777 (LYMPHIR) prior to CAR-T | Phase 1 |
| LYMPHIR | Approved |
| LYMPHIR (denileukin diftitox-cdxl) | Approved |
| LYMPHIR (investigator-initiated: pre-CAR-T) | Phase 1 |
| lymphir was obtained | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$9.1M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 9,188,855 | $5.7M |
| bank of america corp /de/ | 3,835,160 | $2.4M |
| vanguard capital management llc | 1,069,648 | $663K |
| geode capital management, llc | 264,733 | $164K |
| vanguard fiduciary trust co | 121,910 | $76K |
| blackrock, inc. | 47,454 | $29K |
| northern trust corp | 45,746 | $28K |
| state street corp | 42,900 | $27K |
| arkadios wealth advisors | 11,666 | $7K |
| osaic holdings, inc. | 10,125 | $6K |
Showing top 10 of 12 institutional holders of CITIUS ONCOLOGY, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CITIUS ONCOLOGY, INC.'s pipeline?
CITIUS ONCOLOGY, INC. (CTOR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CITIUS ONCOLOGY, INC.'s lead drug candidate?
CITIUS ONCOLOGY, INC.'s most advanced tracked candidate is E7777 (LYMPHIR) prior to CAR-T (Phase 1) for Enhance regulatory T-cell depletion prior to CAR-T therapy for relapsed/refractory B-cell lymphoma (DLBCL).
What is CITIUS ONCOLOGY, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CITIUS ONCOLOGY, INC. has approximately 8.4 months of cash runway.
What is CITIUS ONCOLOGY, INC.'s market capitalization?
CITIUS ONCOLOGY, INC.'s market capitalization is approximately $63.2M.
Who is the CEO of CITIUS ONCOLOGY, INC.?
Mr. Leonard L. Mazur is the chief executive officer of CITIUS ONCOLOGY, INC. (CTOR).
Get the full picture on CITIUS ONCOLOGY, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.